U.S. FDA Grants Fast Track Designation to Astellas for the Development of ASP1128 for Patients at Risk for Acute Kidney Injury

TOKYO, Oct. 28, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials